⌕
Pfizer · PFE · NYSE
Tenet 50 · Mixed
Compare
$28.86−0.10%At closeTenet 50 · Mixed
$28.86−0.03 (−0.10%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$28.860.00 (0.00%)
After hours: Nov 16, 2026, 7:53 PM ET

Pfizer (PFE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PFE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● The Motley FoolNov 16, 2026 · 13:00 ET
2 Stocks With Dividend Yields of 4% or More to Buy in November

Dividend stocks are being forgotten by investors right now. Pfizer has a diversified portfolio with nice growth potential.…

PFE −0.1% todayRead at source ↗
● The Motley FoolNov 14, 2026 · 12:12 ET
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.…

PFE −0.1% todayRead at source ↗
● The Motley FoolNov 14, 2026 · 04:44 ET
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.…

PFE −0.1% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 14:15 ET
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?

Investors are downbeat on Pfizer, at least in part due to concerns about innovation and patent expirations.  The company continues to invest in new drugs, but innovation can't be scheduled.…

PFE −0.1% todayRead at source ↗
● 247 WallstNov 13, 2026 · 11:45 ET
Pfizer Is Up 15.78% This Year, but $1,000 From Five Years Ago Is Still Worth Just $704 With Dividends Reinvested

Pfizer's stock is rallying this year, yet investors who bought near the COVID peak are still underwater, even with every dividend reinvested. A looming 2027 patent test could decide whether that stake ever recovers.…

PFE −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 2
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?

PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation.…

PFE −0.1% todayRead at source ↗
● 247 WallstNov 13, 2026 · 09:17 ET
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer

A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.…

PFE −0.1% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 17:40 ET
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on ke…

PFE −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 10:47 ET
Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program

PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.…

PFE −0.1% todayRead at source ↗
● 247 WallstNov 12, 2026 · 10:42 ET
Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy

Pfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who keeps the upside and what arrives fi…

PFE −0.1% todayRead at source ↗
● BarronsNov 12, 2026 · 09:42 ET
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.…

PFE −0.1% todayRead at source ↗
● WSJNov 11, 2026 · 17:00 ET
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.…

PFE −0.1% todayRead at source ↗
● ReutersNov 11, 2026 · 16:40 ET
Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development…

PFE −0.1% todayRead at source ↗
● Business WireNov 11, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a …

PFE −0.1% todayRead at source ↗
● Business WireNov 10, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Londo…

PFE −0.1% todayRead at source ↗
● The Motley FoolNov 10, 2026 · 06:00 ET
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock

Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.…

PFE −0.1% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:01 ET
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

PFE −0.1% todayRead at source ↗
● The Motley FoolNov 9, 2026 · 09:45 ET
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer acquired a promising GLP-1 drug last year through its purchase of Metsera. It plans to eventually launch both weekly and monthly versions of the treatment.…

PFE −0.1% todayRead at source ↗
● Business WireNov 3, 2026 · 06:45 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXECUTIVE COMMENTARY Dr…

PFE −0.1% todayRead at source ↗
● Business WireNov 3, 2026 · 06:40 ETCOMPANY'S OWN WORDS
Pfizer Appoints Cecile Guegan as Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. …

PFE −0.1% todayRead at source ↗
● Business WireOct 29, 2026 · 11:00 ET
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development

SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.…

PFE −0.1% todayRead at source ↗
● Business WireOct 27, 2026 · 06:45 ETEARNINGS EXPECTED BY FEB 2
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple mye…

PFE −0.1% todayRead at source ↗
● Business WireOct 26, 2026 · 13:41 ET
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treat…

PFE −0.1% todayRead at source ↗
● Business WireOct 24, 2026 · 11:18 ETEARNINGS EXPECTED BY FEB 2
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872…

PFE −0.1% todayRead at source ↗
● Business WireOct 14, 2026 · 06:45 ETCOMPANY'S OWN WORDS
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio a…

PFE −0.1% todayRead at source ↗
● Business WireOct 13, 2026 · 07:00 ET
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules

PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a …

PFE −0.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 2. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA7−4.1%
CATG3−9.9%
DUOT3−7.1%

Article counts from the last market-wide feed page, across every symbol we track and not just PFE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.